From April 21 to 23, the 18th Xiangya International Diabetes Immunology Forum was held in Changsha, China, and hosted by the National Clinical Medical Research Center for Metabolic Diseases, China National Health Association, and Diabetes World Magazine.
Diabetes mellitus encompasses a diverse range of diseases with varying etiologies, pathogenesis, and clinical phenotypes. The emergence of precision medicine offers new approaches and strategies for the in-depth research and clinical prevention and control of diabetes mellitus, and it will have a profound impact on the future diagnosis and treatment of diabetes. In view of this, the forum maintains its focus on "precision diabetology",presenting and discussing the latest advancements in diabetes immunology. The event is dedicated to scientific and clinical research in this field while promoting relevant exchange, collaboration, and translational application, with an aim to enhance the quality of basic and clinical diabetes research in China and support the growth of diabetes precision medicine and diabetes immunology in China.
The forum was chaired by Prof. Zhou Zhiguang, Director of National Clinical Medical Research Center for Metabolic Diseases and Director of Key Laboratory of Diabetes Immunology, Ministry of Education, and Prof. Liu Feng, Chief Expert of the Metabolic Syndrome Research Center, Central South University. The event attracted over 1,000 on-site attendees, with more than 60 distinguished experts and scholars from top diabetes research institutions in the United States, Italy, the United Kingdom, Hong Kong SAR, Mainland China, and other countries and regions delivering engaging academic presentations on both basic and clinical research in the field.
At the conference's opening, Prof. Zhou Zhiguang and Prof. Liu Feng delivered speeches in which they expressed their sincere gratitude to all attending experts and scholars. They acknowledged that the forum's success would not have been possible without the care and support of experts, scholars, and peers from both domestic and international medical communities. They also conveyed their hopes for continued collaboration and progress in order to usher in a new era of precision diabetology.
Liu Bin, Deputy Secretary-General of National Health Association, not only expressed congratulations on the successful convening of the forum on behalf of the association, but also extended a warm welcome and sincere thanks to the presence of experts and scholars. He said the association will persist in its efforts to offer a platform for academic exchanges and promote the prevention and treatment of diabetes nationwide.
The conference also hosted a ceremony to announce the research findings from ADVENT (Adding DPP-4 inhibitor and vitamin D for adult-onset autoimmune diabetes). This study is the first international prospective, multicenter, randomized controlled clinical trial evaluating the safety and efficacy of combining DPP-4 inhibitors with vitamin D in preserving pancreatic β-cell function in adult-onset type 1 diabetes. Prof. Zhou Zhiguang introduced the ADVENT research results to the expert delegates at the conference, which were published online in Signal Transduction and Targeted Therapy (IF=38.1, CAS Q1) on April 20. Then, on behalf of the project team, Prof. Zhou expressed gratitude to researchers from 36 hospitals nationwide and presented them with certificates of honor.
The conference revolved around the new progress in precision diabetes,covering topics from basic research to clinical applications. The event featured sections on precision diabetology (Prof. Wu Hanwen commemorative lecture), precision prediction, precision diagnosis, precision treatment.
